PD-L1 Biomarker Testing Market

Name: pd l1 biomarker testing market
Brand: Future Market Insights
SKU: REP-GB-5897
Price: 5000 USD
Availability: InStock
Rating: 4.8 (14 reviews)

2020 Analysis and Review: PD-L1 Biomarker Testing Market by End-user – Hospitals, Diagnostic Laboratories, and Specialty Clinics for 2020 – 2030

2020-10-16
REP-GB-5897
300 pages
Healthcare

Introduction

The term biomarker refers to a human’s body molecule - obtained from blood, body fluids, or tissue - that can be studied to assess the health of the person. Testing a human for existing diseases through biomarkers and assessing molecular signs of health is called biomarker testing.

PD-L1, a protein whose presence indicates a tumor, emerged as an early biomarker to be tested in immunotherapy clinical trials.

Contrary to conventional standards, the ability to assess each individual distinctively, solely based on the levels of PD-L1 protein, makes it one of the most reliable tests available in the industry currently.

PD-L1 biomarker testing is majorly used as a cancer diagnostic and analysis process to detect early-stage non-small cell lung cancer and melanoma. Also known as molecular testing and targeted therapy, PD-L1 biomarker testing is known for its providing accurate results by studying the molecular underpinning of an individual patient's diseases.

Moreover, it finds application in the cancer treatment process, tracking the growth of cancer, and measuring the progress of the treatment. Over the years, biomarker testing has become an integral part of the diagnosis and treatment process of non-small lung cancer, gaining the trust of medical professions and patients alike.

As the incidence of different types of malignant cancers continues to rise year-on-year, there is a persistent demand for effective diagnostic solutions. This is expected to remain the principal driving factor for the adoption of PD-L1 biomarker testing.

Increasing Prevalence of Lung Cancer

Continual adoption in the diagnosis of non-small cell lung cancer is poised to remain the crucial growth attribute to the biomarker testing market. Among the total number of lung cancer cases diagnosed, 84% of them are non-small cell lung cancers.

Similarly, according to the World Health Organization (WHO), lung cancer is the most prevalent cancer, causing nearly 2 Mn deaths in 2018. In the US, the number of deaths due to lung cancer peaked in 2005 with 159,292 deaths. In 2020, as of now, over 228,820 new cases and 135,720 new cases have been registered, according to the statistics of the American Cancer Society.

Developed economies such as the US are focusing on reducing the deaths through early screenings and awareness programs, thus necessitating effectual testing methodologies.

The US Centers for Diseases Control and Prevention (CDC) linked over 80% of lung cancer cases to smoking. Owing to the increasing number of smokers every year, the number of lung cancer patients is anticipated to remain high worldwide.

On the other hand, medical professionals in India have opposed the connection between smoking and lung cancer, citing the 30% to 40% increase in incidence among non-smokers.

However, other micro factors such as drinking or obesity, and macro factors such as alarming levels of air pollution have been identified as significant causes of lung cancers.

On the back of these facets, the number of lung cancer cases is expected to prevail worldwide, consequentially increasing the need for PD-L1 biomarker testing is poised to remain high through the forecast period.

Ease of Use

PD-L1 biomarker testing has emerged as an effective diagnostic method, aiding medical professionals in making timely, appropriate decisions during the treatment process.

More importantly, the testing reveals whether the patient has a treatable driver mutation and establishes the patient's PD-L1 protein expression level, thereby bolstering medical experts in choosing the right treatment process.

PD-L1 biomarker testing has significantly improved early-stage detection rates and has received support from healthcare institutions for wide-scale usage. Over 15 different types of biomarker-based targeted therapies for lung cancer patients with adenocarcinoma are approved by the US Food and Drug Administration (FDA).

In a similar vein, several drugs are prescribed by professionals solely based on the levels of PD-L1 in the patient’s body. As a result, PD-L1 biomarker testing has established itself as the first preference as a predictive biomarker.

Being one of the very few biomarkers approved for testing, PD-L1 biomarker testing is relatively easier to conduct and consumes less time to read and comprehend the results. On this premise, biomarkers have become a reliable source of testing among individuals and laboratories, thus driving the market on a positive growth trajectory through the forecast period

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on pd l1 biomarker testing market

Know Report Methodology

Precision Remains a Subject of Debate

A few studies and claims have challenged the precision and efficiency of PD L1 biomarker test. According to a report published in the Journal for ImmunoTherapy of Cancer, although PD-L1 received approval for testing 15 types of tumors, PD-L1 has been successful in predicting only 28.9% of these cases.

The study went on to reveal that PD-L1 biomarker testing could not predict over 53.3% of cases while 17.8% of cases remained untested. These limitations pose a significant threat to PD-L1 biomarker testing’s standpoint as a predictive testing methodology.

Another study related to the performance of testing using immunohistochemistry found it inefficient, questioning the standards used in the process to measure the positivity of the disease.

The study further found that there is no consensus on the relevance of patterns of expression such as immune infiltrating lymphocytes, membranous vs cytoplasmic, shedding light on the cracks of the process.

Although medical professionals have cited differing characteristics of biomarkers as the cause for fluctuating results, this is expected to limit the adoption of PD-L1 biomarker testing to an extent.

Region-wise Analysis

North America PD-L1 Biomarker Testing Market

North America - led by the US - is projected to remain the largest market for PD-L1 biomarker testing market, capturing nearly half of the global market value. The region's dominance is majorly attributed to the high prevalence of lung cancer, coupled with the presence of advanced medical infrastructure in the region.

PD-L1 biomarker testing is also used in the diagnosis of melanoma, a type of skin cancer, whose incidence has been rising in the US over the past few decades. In the US alone, more than 100,000 new cases of melanoma are expected to be diagnosed in 2020. This bestows a huge opportunity for PD-L1 biomarker testing.

Similarly, lung cancer has remained one of the major causes of death in the nation for years and will continue to steer the adoption of the PD-L1 biomarker testing for the years to come.

Request a sample specific to North America Market

Europe PD-L1 Biomarker Testing Market

Europe will prevail as the second most lucrative region through the assessment period and will account for more than 1/3rd of market value by the end of 2030. Akin to the North American region, the growth of PD-L1 biomarker testing industry in Europe is attributed to the high incidence of lung cancer in the region. Europe is also home to a large oncology drug market.

Lung cancer is the leading cause of cancer-related deaths in Europe, having claimed more than 380,000 lives in 2018, representing 1 in every 5 cancer deaths. With the diagnosis of 470,000 cases in 2018, Europe accounts for nearly 23% of the total number of cancer cases.

Moreover, healthcare bodies in the region are working on raising awareness among patients regarding the availability of biomarkers. In 2018, the European Cancer Patient Coalition (ECPC) launched an educational video animation on biomarkers, along with an infographic and dedicated webpage to increase awareness regarding the testing.

In the same year, ECPC collaborated with Cancer Drug Development Forum (CDDF) to organize a workshop on biomarkers and patients’ access to personalized oncology drugs in Europe. Such initiatives will continue to propel the adoption of biomarkers in the region.

Request a sample specific to Europe Market

East Asia PD-L1 Biomarker Testing Market

Although relatively lower in value as compared to North America and Europe, East Asia will remain a prominent region through the forecast period, growing in value at a healthy pace. The lung cancer diagnostic market in itself is quite expansive, and use of PD-L1 biomarker testing is a component of it.

In 2015, approximately 733,000 new lung cancer cases and 610,000 deaths, representing 21.7% of total cancer mortality were registered in China. Similarly, the number of lung cancer cases grew exponentially in Japan in the last few decades.

On the back of the soaring incidence of lung cancer, the demand for biomarkers will persist in the forthcoming years.

Request a sample specific to East Asia Market

Category-wise Insights

PD-L1 SP142 Remains Most Sought-after

By product type, PD-L1 SP142 assay kits are expected to remain the most sought out product, capturing nearly 50% of global value. High preference for these kits is ascribed to its robustness and efficiency in detecting tumors at a very early stage.

Likewise, PD-L1 SP263 assay kits are gradually gaining prominence in the detection of lung cancer and the segment is poised to grow in value in the forthcoming years.

Non-small Cell Lung Cancer Accounts for High Share

Non-small cell lung cancer and melanoma are expected to collectively account for over half of the global market value, with the former holding the lion's share. This is primarily attributed to the surging prevalence of these diseases across the world and the subsequent demand for accurate diagnostic methods.

End-user: Hospitals Channel Majority of Revenue

On the basis of end-use, hospitals are expected to drive the majority of revenue, accounting for more than 3/5th of sales. Hospitals are poised to remain the most preferred healthcare institution among consumers owing to the availability of advanced tools and infrastructure.

Competitive Landscape

On the research and development front, PD-L1 biomarker testing product manufacturers are focusing on enhancing the accuracy and accessibility of testing. Besides, they are working on reducing operational expenses to ensure their products remain cost-effective.

On the strategic front, players are adopting organic strategies such as partnerships and acquisitions to expand their brand visibility. On these lines, in January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities. Similarly, in December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.